Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Phase 1 Completed 12 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of irofulven in treating children with recurrent or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells so they stop growing or die.

Timeline

Start: 1998-08
Primary completion: 2006-03
Completion: —

Publications

Results Bomgaars LR, Megason GC, Pullen J, Langevin AM, Dale Weitman S, Hershon L, Kuhn JG, Bernstein M, Blaney SM. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Aug;47(2):163-8. doi: 10.1002/pbc.20686.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	irofulven	Small molecule	6 mg/m2	Intravenous
Subject	irofulven	Small molecule	8 mg/m2	Intravenous
Subject	irofulven	Small molecule	10 mg/m2	Intravenous
Subject	irofulven	Small molecule	13 mg/m2	Intravenous
Subject	irofulven	Small molecule	17 mg/m2	Intravenous

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Summary

Timeline

Publications

Drugs

Indications